Is Novo Nordisk (NYSE:NVO) Price Weakness Creating A Potential Valuation Opportunity?

Simply Wall St.04-23 02:11

If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent performance gives you plenty to think about. The stock last closed at US$39.42, with returns of 0.3%...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2629202419?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-04-23 02:11","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2629202419","market":"hk","top_or_hot":-1,"title":"Is Novo Nordisk (NYSE:NVO) Price Weakness Creating A Potential Valuation Opportunity?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent performance gives you plenty to think about. The stock last closed at US$39.42, with returns of 0.3%...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-price-weakness-creating-a-potential\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Novo Nordisk (NYSE:NVO) Price Weakness Creating A Potential Valuation Opportunity?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Novo Nordisk (NYSE:NVO) Price Weakness Creating A Potential Valuation Opportunity?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-23 02:11 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-price-weakness-creating-a-potential><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent performance gives you plenty to think about. The stock last closed at US$39.42, with returns of 0.3%...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-price-weakness-creating-a-potential\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00BZ1G4Q59.USD","symbol_name":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-price-weakness-creating-a-potential","article_id":"2629202419","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-nvo/novo-nordisk/news/is-novo-nordisk-nysenvo-price-weakness-creating-a-potential","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2629202419","pubTimestamp":1776881512,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent performance gives you plenty to think about.\nThe stock last closed at US$39.42, with returns of 0.3% over 7 days and 7.9% over 30 days, but declines of 24.8% year to date and 32.0% over the past year, setting up a very mixed picture.\nThese moves have arrived as investors continue to reassess large pharmaceutical names and focus more on valuations and pipelines. Novo Nordisk is frequently at...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","BK4585":"ETF&股票定投概念","NVO":"诺和诺德","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4532":"文艺复兴科技持仓","NVOX":"2倍做多NVO ETF-Defiance","NVOH":"Novo Nordisk A/S B Shares ADRhedged","BK4007":"制药","BK4599":"减肥药","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","BK4588":"碎股","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD"},"translate_title":"诺和诺德（纽约证券交易所股票代码：NVO）的价格疲软是否创造了潜在的估值机会？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NVOH":0.6,"NVOX":0.6,"NVO":1.98},"content_text":"If you are wondering whether Novo Nordisk's current share price reflects its true worth, the recent performance gives you plenty to think about. The stock last closed at US$39.42, with returns of 0.3% over 7 days and 7.9% over 30 days, but declines of 24.8% year to date and 32.0% over the past year, setting up a very mixed picture. These moves have arrived as investors continue to reassess large pharmaceutical names and focus more on valuations and pipelines. Novo Nordisk is frequently at the center of this discussion. That shift in attention helps explain why the share price and perceived risk profile have been in focus even without a single headline event driving the latest move. Novo Nordisk currently scores 5 out of 6 on Simply Wall St's valuation checks, as shown by its valuation score. The next step is to look at how different valuation methods line up, before turning to an approach at the end of the article that can help you understand that valuation in a more rounded way.  Find out why Novo Nordisk's -32.0% return over the last year is lagging behind its peers. AdvertisementApproach 1: Novo Nordisk Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model takes estimates of the cash a company may generate in the future, then discounts those cash flows back to today to arrive at an implied value per share. For Novo Nordisk, the model used here is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is DKK 52,097.16m. Analyst inputs and Simply Wall St extrapolations project free cash flow reaching DKK 107,429.50m by 2030, with interim projections such as DKK 44,924.14m in 2026 and DKK 92,055.00m in 2029. These figures are all in DKK, which is the company’s reporting currency, even though the shares trade in US$. When these projected cash flows are discounted back to today, the model arrives at an estimated intrinsic value of US$112.63 per share, compared with the recent share price of US$39.42. That implies Novo Nordisk trades at a 65.0% discount to this DCF estimate and suggests the shares are significantly below the modelled value. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Novo Nordisk is undervalued by 65.0%. Track this in your watchlist or portfolio, or discover 58 more high quality undervalued stocks. NVO Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Novo Nordisk. Approach 2: Novo Nordisk Price vs Earnings For a profitable company like Novo Nordisk, the P/E ratio is a useful way to relate what you pay per share to the earnings that each share generates. Investors usually look for a P/E that makes sense relative to a company’s growth outlook and risk profile, since higher growth or lower risk can support a higher “normal” P/E, while slower growth or higher risk can justify a lower one. Novo Nordisk currently trades on a P/E of 10.7x. That sits below the Pharmaceuticals industry average of about 16.2x and also below the peer group average of 19.6x. Simply Wall St’s Fair Ratio for Novo Nordisk is 25.0x, which is its view of what the P/E might look like after factoring in the company’s earnings growth outlook, profit margins, industry, market cap and risk characteristics. This Fair Ratio is designed to be a more tailored benchmark than a simple comparison with industry or peer averages, because it adjusts for company specific factors rather than assuming that all drug makers should trade at the same multiple. Comparing Novo Nordisk’s current P/E of 10.7x with the Fair Ratio of 25.0x points to the shares trading below that tailored benchmark. Result: UNDERVALUED NYSE:NVO P/E Ratio as at Apr 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Novo Nordisk Narrative Earlier it was mentioned that there is an even better way to understand valuation. This is where Narratives come in, letting you attach a clear story about Novo Nordisk to your own assumptions for future revenue, earnings, margins and fair value, then compare that fair value with the current price in a simple, visual way. A Narrative on Simply Wall St’s Community page connects what you think is happening with the business to a set of numbers in a forecast, and then into a fair value. Instead of only looking at a P/E or DCF output, you see how the story and the numbers fit together. Because these Narratives update when new information like news or earnings is added, you can quickly see whether your story about Novo Nordisk still holds, or whether the gap between your fair value and the share price has moved enough to consider adjusting your position, without needing to rebuild a full model each time. For example, one Novo Nordisk Narrative on the platform currently assigns a fair value of about US$95 per ADR, while another uses different assumptions to arrive near US$65.50. This shows how two investors looking at the same company can reach very different yet clearly explained conclusions about what the stock is worth today. Do you think there's more to the story for Novo Nordisk? Head over to our Community to see what others are saying! NYSE:NVO 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Novo Nordisk might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2629202419","isCrawlerRequest":true}